Previous Page  12 / 32 Next Page
Information
Show Menu
Previous Page 12 / 32 Next Page
Page Background

AMERICAN SOCIETY OF CLINICAL ONCOLOGY 2016 ANNUAL MEETING

12

PRACTICEUPDATE HAEMATOLOGY & ONCOLOGY

Mekinist

®

(trametinib dimethyl sulfoxide) in combination with Tafinlar

®

(dabrafenib mesilate)

Please review full Mekinist

®

(trametinib dimethyl sulfoxide) and Tafinlar

®

(dabrafenib mesilate) product

information before prescribing. Approved product information is available on request or online at

www.novartis.com.au/products/healthcare-professionals.shtml.

PBS Information:

MEKINIST (trametinib)

. Authority Required (STREAMLINED). Treatment of BRAF V600 mutation positive unresectable

Stage III or Stage IV (metastatic) melanoma in combination with dabrafenib. Refer to the PBS Schedule for full Authority information.

PBS Information:

TAFINLAR (dabrafenib)

. Authority Required (STREAMLINED).

Treatment of BRAF V600 mutation positive unresectable Stage III or Stage IV (metastatic) melanoma. Refer to the PBS Schedule

for full Authority information.